Dr. Deborah Y. Chong, MD

Dr. Chong practices at Texas Retina Associates in Rockwall, Texas.

Dr. Chong's NPI, 1841318284, was assigned on March 26, 2007. Dr. Chong graduated from Harvard Medical School in 2004. Dr. Chong's Texas license number on file is M9215.

Dr. Chong's primary practice is Texas Retina Associates, at 2380 S Goliad St, Rockwall, TX 75032 in Rockwall County. The practice phone is (903) 893-8443.

Dr. Chong's primary practice is Texas Retina Associates in Rockwall, Texas. Dmand AI also links Dr. Chong to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chong practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Chong's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Chong is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Chong's licenses on file in 2 states: Texas and Michigan.

Dmand AI lists age-related macular degeneration, cataract, dry eye, eyelid inflammation, glaucoma, inflammation of iris, laser destruction of retinal or choroid lesions and retinal detachment among the conditions Dr. Chong treats.

CMS data shows 25,291 Medicare services from Dr. Chong across 22 procedure codes in 2024, for 884 Medicare patients. Medicare paid $2,208,794 for them.

CMS counts 884 Medicare patients who saw Dr. Chong in 2024. The largest group is 65 to 74, with 373 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.32, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chong's median patient age at 72, with 54% women.

In 2024, Dr. Chong wrote 607 Medicare Part D claims for 188 patients. 49% of them were for generic drugs. CMS names the drug for 560 of them, across 9 drugs with 11 or more claims each, at $48,136 in total drug cost. In 2023, CMS named 460 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Chong for performance year 2024, reported as part of a group. Dr. Chong accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Chong, published from 2008 to 2009. The most frequent topics are Vascular Endothelial Growth Factor A, Vitreous Body and Angiogenesis Inhibitors. Dr. Chong has published most often in Arch Ophthalmol. Dr. Chong's most frequent co-authors are David G. Callanan, MD, Patrick D. Williams, MD and Rajiv Anand, MD.

CMS Open Payments shows 123 general payments to Dr. Chong from 20 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 52% of the total. Genentech, Inc. paid the most, $5,437.

Dmand AI lists 1 award for Dr. Chong, most recently CMS Stage 1 EHR in 2013.

Dr. Chong graduated from Harvard Medical School in 2004. Dr. Chong is a member of AAO.

Dr. Chong is in network with 18 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.